Biogen stops Phase II for returned IPF candidate

Seven years after regaining rights to BG00011 (STX-100), Biogen terminated its Phase II trial of the mAb for idiopathic pulmonary fibrosis (IPF) due to safety concerns.

Biogen Inc. (NASDAQ:BIIB) had licensed the humanized mAb against integrin αvβ6 to Stromedix Inc. in 2007 after shelving the program a first time in 2006. The company regained rights to the compound in 2012, when it acquired Stromedix for $75 million up front and up to $487.5 million in milestones (see "Biogen Buys Back In")...